Cerevel Therapeutics Holdings, Inc.
CERENASDAQHealthcare
$44.96
+$0.33(+0.74%)
Market Cap$8.2B
P/E Ratio—
52W High$44.99
52W Low$19.59
Cerevel Therapeutics Holdings, Inc. (CERE) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CERE · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.01B) | ($0.00B) | ($0.00B) | ($0.00B) | $0.00B |
| Gross Margin %(computed) | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.33B | $0.28B | $0.16B | $0.10B | $0.05B |
| G&A Expenses | $0.11B | $0.09B | $0.06B | $0.05B | $0.03B |
| Total Operating Expenses | $0.47B | $0.37B | $0.22B | $0.15B | $0.08B |
| Operating Income | ($0.45B) | ($0.37B) | ($0.22B) | ($0.15B) | ($0.08B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.04B | $0.01B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.01B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.43B) | ($0.35B) | ($0.23B) | ($0.15B) | ($0.13B) |
| Income Tax Expense | $0.00B | $0.00B | ($0.00B) | ($0.00B) | $0.00B |
| Net Income | ($0.43B) | ($0.35B) | ($0.22B) | ($0.15B) | ($0.13B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.67 | $-2.32 | $-1.63 | $-1.29 | $-1.01 |
| Wtd Avg Shares | 0.16B | 0.15B | 0.14B | 0.12B | 0.13B |
| EBITDA | ($0.42B) | ($0.34B) | ($0.21B) | ($0.15B) | ($0.04B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Cerevel Therapeutics Holdings, Inc. data
About Cerevel Therapeutics Holdings, Inc. (CERE) Income Statement
Cerevel Therapeutics Holdings, Inc. (CERE) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, CERE reported revenue of $0.00B, gross profit of ($0.01B) (gross margin —), and net income of ($0.43B) — a net profit margin of —.
Frequently asked questions
CERE · 4 questionsCerevel Therapeutics Holdings, Inc. (CERE) reported revenue of $0.00B for 2023, down —% year-over-year.
CERE revenueCERE salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09